Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients
Open accessThe DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
BACKGROUND: TGF-β has potent profibrotic activity in vitro and has long been implicated in systemic sclerosis (SSc), as expression of TGF-β-regulated genes is increased in the skin and lungs of patients with SSc. Therefore, inhibition of TGF-β may benefit these patients. METHODS: Patients with early, diffuse cutaneous SSc were enrolled in an open-label trial of fresolimumab, a high-affinity neutralizing antibody that targets all 3 TGF-β isoforms. Seven patients received two 1 mg/kg doses of fresolimumab, and eight patients received one 5 mg/kg dose of fresolimumab. Serial mid-forearm skin biopsies, performed before and after treatment, were analyzed for expression of the TGF-β-regulated biomarker genes thrombospondin-1 (THBS1) and cartilage oligomeric protein (COMP) and stained for myofibroblasts. Clinical skin disease was assessed using the modified Rodnan skin score (MRSS). RESULTS: In patient skin, THBS1 expression rapidly declined after fresolimumab treatment in both groups (P = 0.0313 at 7 weeks and P = 0.0156 at 3 weeks), and skin expression of COMP exhibited a strong downward trend in both groups. Clinical skin disease dramatically and rapidly decreased (P < 0.001 at all time points). Expression levels of other TGF-β-regulated genes, including SERPINE1 and CTGF, declined (P = 0.049 and P = 0.012, respectively), and a 2-gene, longitudinal pharmacodynamic biomarker of SSc skin disease decreased after fresolimumab treatment (P = 0.0067). Dermal myofibroblast infiltration also declined in patient skin after fresolimumab (P < 0.05). Baseline levels of THBS1 were predictive of reduced THBS1 expression and improved MRSS after fresolimumab treatment. CONCLUSION: The rapid inhibition of TGF-β-regulated gene expression in response to fresolimumab strongly implicates TGF-β in the pathogenesis of fibrosis in SSc. Parallel improvement in the MRSS indicates that fresolimumab rapidly reverses markers of skin fibrosis. TRIAL REGISTRATION: Clinicaltrials.gov NCT01284322.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a small open label single center study, Fresolimumab (180), a high affinity TGFβ inactivating monoclonal antibody was recently tested in SSc patients, and reduced TGFβ dependent gene expression in skin biopsies and improved modified Rodnan skin score (180).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [180]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preliminary criteria for the classification of systemic sclerosis (scleroderma)
Masi, A. T., & Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230510 · Cited by 4,898
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis
(2001) · Classic Papers in Rheumatology · doi:10.3109/9780203214237-95 · Cited by 3,950
Open source clustering software
de Hoon, M. J. L., Imoto, S., Nolan, J., & Miyano, S. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth078 · Cited by 3,043
Roberts, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Roche, N. S., Wakefield, L. M., Heine, U. I., Liotta, L. A., Falanga, V, & Kehrl, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4167 · Cited by 2,866
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Self-citationTransforming growth factor type beta induces monocyte chemotaxis and growth factor production.
Wahl, S. M., Hunt, D. A., Wakefield, L. M., McCartney-Francis, N., Wahl, L. M., Roberts, A. B., & Sporn, M. B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5788 · Cited by 1,272
Systemic sclerosis: a prototypic multisystem fibrotic disorder
Varga, J., & Abraham, D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31139 · Cited by 1,163
Type beta transforming growth factor: a bifunctional regulator of cellular growth.
Roberts, A. B., Anzano, M. A., Wakefield, L. M., Roche, N. S., Stern, D. F., & Sporn, M. B. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.1.119 · Cited by 1,094
NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury
Hecker, L., Vittal, R., Jones, T., Jagirdar, R., Luckhardt, T. R., Horowitz, J. C., Pennathur, S., Martinez, F. J., & Thannickal, V. J. (2009) · Nature Medicine · doi:10.1038/nm.2005 · Cited by 852 · cited 3×
“In addition microarray analyses showed that downregulation of these genes was associated with downregulated expression of a larger cluster of known TGF-β– regulated genes, including NOX4 and CTGF, both implicated as secondary mediators of TGF-β signaling (21, 32).”
Backgroundvan Laar, J. M., Farge, D., Sont, J. K., Naraghi, K., Marjanovic, Z., Larghero, J., Schuerwegh, A. J., Marijt, E. W. A., Vonk, M. C., Schattenberg, A. V., et al. (2014) · JAMA · doi:10.1001/jama.2014.6368 · Cited by 766
Transforming Growth Factor‐β: Major Role in Regulation of Extracellular Matrix
ROBERTS, A. B., HEINE, U. I., FLANDERS, K. C., & SPORN, M. B. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb17931.x · Cited by 696
Morris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090353 · Cited by 487 · cited 1×
“We did not see keratoacanthomas in our study; however, several patients had epistaxis, gum bleeding, or subconjunctival eye hemorrhage, as reported in other studies of fresolimumab (46, 47).”
ResultElhai, M., Meune, C., Avouac, J., Kahan, A., & Allanore, Y. (2012) · Rheumatology · doi:10.1093/rheumatology/ker269 · Cited by 460
Denton (2007) · doi:10.1002/art.22289 · Cited by 447
Interstitial lung disease in connective tissue disorders
Fischer, A., & du Bois, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61079-4 · Cited by 430
Dulauroy, S., Di Carlo, S. E., Langa, F., Eberl, G., & Peduto, L. (2012) · Nature Medicine · doi:10.1038/nm.2848 · Cited by 418 · cited 1×
“Notably, in recent studies, ADAM12+ pericytes were shown to be progenitors of myofibroblasts induced after skin or muscle injury, and deletion of ADAM12+ cells blocked fibrosis (38).”
ResultPenttinen, R. P., Kobayashi, S., & Bornstein, P. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.4.1105 · Cited by 415
Igarashi, A., Nashiro, K., Kikuchi, K., Sato, S., Ihn, H., Grotendorst, G. R., & Takehara, K. (1995) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12318465 · Cited by 277
Trachtman, H., Fervenza, F. C., Gipson, D. S., Heering, P., Jayne, D. R. W., Peters, H., Rota, S., Remuzzi, G., Rump, L. C., Sellin, L. K., et al. (2011) · Kidney International · doi:10.1038/ki.2011.33 · Cited by 263
Lund, L. R., Riccio, A., Andreasen, P. A., Nielsen, L. S., Kristensen, P., Laiho, M., Saksela, O., Blasi, F., & Danø, K. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02365.x · Cited by 247
[Interstitial lung disease in connective tissue disorders].
Carmier, D., Diot, É., Guilleminault, L., & Marchand-Adam, S. (2014) · PubMed · Cited by 237
Autoantibody Reactive with RNA Polymerase III in Systemic Sclerosis
Okano, Y., Steen, V. D., & Medsger, T. A. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-10-199311150-00007 · Cited by 207
Sonnylal, S., Shi‐Wen, X., Leoni, P., Naff, K., Van Pelt, C. S., Nakamura, H., Leask, A., Abraham, D., Bou‐Gharios, G., & de Crombrugghe, B. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27382 · Cited by 196
Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma
Gerber, E. E., Gallo, E. M., Fontana, S. C., Davis, E. C., Wigley, F. M., Huso, D. L., & Dietz, H. C. (2013) · Nature · doi:10.1038/nature12614 · Cited by 190
A four‐gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis
Farina, G., Lafyatis, D., Lemaire, R., & Lafyatis, R. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27220 · Cited by 170
Self-citationActivation of the TGF- β/Smad signaling pathway in focal segmental glomerulosclerosis
Kim, J. H., Kim, B. K., Moon, K. C., Hong, H. K., & Lee, H. S. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00288.x · Cited by 158
Heart involvement in systemic sclerosis: Evolving concept and diagnostic methodologies
Meune, C., Vignaux, O., Kahan, A., & Allanore, Y. (2009) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2009.06.009 · Cited by 145
Amjadi, S., Maranian, P., Furst, D. E., Clements, P. J., Wong, W. K., Postlethwaite, A. E., Khanna, P. P., & Khanna, D. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24681 · Cited by 141
Mehlhorn, A. T., Niemeyer, P., Kaschte, K., Muller, L., Finkenzeller, G., Hartl, D., Südkamp, N. P., & Schmal, H. (2007) · Cell Proliferation · doi:10.1111/j.1365-2184.2007.00473.x · Cited by 139
Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis
Kissin, E. Y., Merkel, P. A., & Lafyatis, R. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22186 · Cited by 123 · cited 3×
“Myofibroblasts are sensitive markers of SSc skin disease, and the intensity of myofibroblast infiltration correlates highly with the severity of skin disease, as assessed by the MRSS (26).”
BackgroundMethodInfluentialSelf-citationAtfi, A., Dumont, E., Colland, F., Bonnier, D., L'Helgoualc'h, A., Prunier, C., Ferrand, N., Clément, B., Wewer, U. M., & Théret, N. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200612046 · Cited by 119
Sobanski, V., Dauchet, L., Lefèvre, G., Lambert, M., Morell‐Dubois, S., Sy, T., HACHULLA, E., Hatron, P., Launay, D., & Dubucquoi, S. (2013) · Arthritis & Rheumatology · doi:10.1002/art.38219 · Cited by 111
Mechanisms and consequences of TGF-ß overexpression by podocytes in progressive podocyte disease
Lee, H. S. (2011) · Cell and Tissue Research · doi:10.1007/s00441-011-1169-7 · Cited by 110
Rice, L. M., Ziemek, J., Stratton, E. A., McLaughlin, S. R., Padilla, C. M., Mathes, A. L., Christmann, R. B., Stifano, G., Browning, J. L., Whitfield, M. L., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39287 · Cited by 106
Self-citationHow Does TGF-β Mediate Tubulointerstitial Fibrosis?
Gewin, L. S., & Zent, R. (2012) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2012.04.001 · Cited by 93
Laser Capture Microdissection-Microarray Analysis of Focal Segmental Glomerulosclerosis Glomeruli
BENNETT, M. R., Czech, K. A., Arend, L. J., Witte, D. P., Devarajan, P., & Potter, S. S. (2007) · Nephron Experimental Nephrology · doi:10.1159/000106775 · Cited by 86
Stevenson, J. P., Kindler, H. L., Papasavvas, E., Sun, J., Jacobs-Small, M., Hull, J., Schwed, D., Ranganathan, A., Newick, K., Heitjan, D. F., et al. (2013) · OncoImmunology · doi:10.4161/onci.26218 · Cited by 85
Merkel, P. A., Silliman, N. P., Clements, P. J., Denton, C. P., Furst, D. E., Mayes, M. D., Pope, J. E., Polisson, R. P., Streisand, J. B., Seibold, J. R., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34427 · Cited by 76
Idiopathic Pulmonary Fibrosis: Pathobiology of Novel Approaches to Treatment
Maher, T. M. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.11.002 · Cited by 69
Wu, M., Pedroza, M., Lafyatis, R., George, A., Mayes, M. D., Assassi, S., Tan, F. K., Brenner, M. B., & Agarwal, S. K. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38275 · Cited by 68
Self-citationVarga, J., Wigley, F. M., & Denton, C. P. (2011) · Springer eBooks · doi:10.1007/978-1-4419-5774-0 · Cited by 51
Inagaki, Y., Higashiyama, R., & Higashi, K. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07006.x · Cited by 43
Clinical trials in systemic sclerosis: lessons learned and outcomes
Matucci‐Cerinic, M., Steen, V. D., Furst, D. E., & Seibold, J. R. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2191 · Cited by 40
NEGOESCU, A., Lafeuillade, B., Pellerin, S., CHAMBAZ, E. M., & Feige, J. (1995) · Experimental Cell Research · doi:10.1006/excr.1995.1103 · Cited by 33
Regulation of Renal Fibrosis by Smad3 Thr388 Phosphorylation
Qu, X., Li, X., Zheng, Y., Ren, Y., Puelles, V. G., Caruana, G., Nikolic-Paterson, D. J., & Li, J. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.12.003 · Cited by 33 · cited 1×
“In patients with focal segmental glomerulosclerosis (FSGS), fresolimumab treatment was associated with a decline in proteinuria in some patients, suggesting possible efficacy in this disease, for which TGF-β is also strongly implicated in pathogenesis (41, 42).”
BackgroundKim, Y. M., Kim, J. J., Heo, S. C., Shin, S., Do, E. K., Suh, D., Kim, K., Yoon, M., Lee, T. G., & Kim, J. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040820 · Cited by 32
Zhou, X., Xiong, M., Tan, F., Guo, X., & Arnett, F. C. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22249 · Cited by 22
Development of an in vitro potency assay for therapeutic TGFβ antagonists: The A549 cell bioassay
Rapoza, M. L., Fu, D., & Sendak, R. A. (2006) · Journal of Immunological Methods · doi:10.1016/j.jim.2006.07.009 · Cited by 16
Shigeyama (2000) · doi:10.1002/1529-0131(200011)43:11
Research works printed but not linked: 4
- Derynck R, Miyaono K, eds. The TGF-Beta Family. Cold Spring Harbor Monograph Series 50. Cold Spring Harbor, New York, USA: Cold Spring Harbor Laboratory Press; 2007.
- 10.1002/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q · doi:10.1002/1529-0131(200011)43:11<2445::aid-anr11>3.0.co;2-q
- Rice, Arthritis Rheum.
- LeRoy, 1988, J Rheumatol., 15, 202
Cited by
TGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528
Denton, C. P., & Khanna, D. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30933-9 · Cited by 2,212
Transforming growth factor–β in tissue fibrosis
Frangogiannis, N. G. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190103 · Cited by 1,278
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,168
Metadata
- Authors
- Rice, L. M., Padilla, C. M., McLaughlin, S. R., Mathes, A., Ziemek, J., Goummih, S., Nakerakanti, S., York, M., Farina, G., Whitfield, M. L., Spiera, R. F., Christmann, R. B., Gordon, J. K., Weinberg, J., Simms, R. W., & Lafyatis, R.
- Affiliations
- Boston University (US)
- Hospital for Special Surgery (US)
- Dartmouth College (US)
- Corresponding author
- Lafyatis, Robert
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2015-06-22
- Volume
- 125
- Issue
- 7
- Pages
- 2795-2807
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4563675
- OpenAlex
- W2155049325
- Cited by
- 351
- References
- 53
- Citations by year
- 2026: 19 · 2025: 26 · 2024: 30 · 2023: 27 · 2022: 37 · 2021: 30 · 2020: 28 · 2019: 24 · 2018: 42 · 2017: 41 · 2016: 34 · 2015: 13
- FWCI
- 34.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Scleroderma Research Foundation
- Bristol-Myers Squibb
- GlaxoSmithKline
- Gilead Sciences
- Alexion Pharmaceuticals
- Celgene
- United Therapeutics Corporation
- Dr. Ralph and Marian Falk Medical Research Trust
- Hospital for Special Surgery
- Cytori Therapeutics
- National Institutes of Health
- Genentech
- Clinical and Translational Science Institute, Boston University
- National Cancer Institute (P30CA023108)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR051089, R03AR062721, P30AR061271, P50AR060780)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
- Keywords
- systemic sclerosis, diffuse cutaneous systemic sclerosis, TGF-beta inhibition, skin fibrosis, thrombospondin-1, cartilage oligomeric matrix protein, myofibroblasts, connective tissue growth factor, SERPINE1, modified Rodnan skin score, pharmacodynamic biomarkers, neutralizing antibodies
- MeSH terms
- Adult, Antibodies, Monoclonal, Female, Genetic Markers, Humans, Male, Middle Aged, Scleroderma, Systemic, Gene Expression, Transforming Growth Factor beta, Treatment Outcome, Thrombospondin 1, Myofibroblasts, Antibodies, Monoclonal, Humanized, Cartilage Oligomeric Matrix Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.